136 related articles for article (PubMed ID: 32777186)
1. Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report.
Lutz J; Dunaj-Kazmierowska M; Arcan S; Kassner U; Miyashita K; Murakami M; Ploug M; Fong LG; Young SG; Nakajima K; Beigneux AP
Ann Intern Med; 2020 Nov; 173(9):764-765. PubMed ID: 32777186
[No Abstract] [Full Text] [Related]
2. Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.
Beigneux AP; Miyashita K; Ploug M; Blom DJ; Ai M; Linton MF; Khovidhunkit W; Dufour R; Garg A; McMahon MA; Pullinger CR; Sandoval NP; Hu X; Allan CM; Larsson M; Machida T; Murakami M; Reue K; Tontonoz P; Goldberg IJ; Moulin P; Charrière S; Fong LG; Nakajima K; Young SG
N Engl J Med; 2017 Apr; 376(17):1647-1658. PubMed ID: 28402248
[TBL] [Abstract][Full Text] [Related]
3. Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.
Ashraf AP; Miyashita K; Nakajima K; Murakami M; Hegele RA; Ploug M; Fong LG; Young SG; Beigneux AP
J Clin Lipidol; 2020; 14(2):197-200. PubMed ID: 32107180
[TBL] [Abstract][Full Text] [Related]
4. GPIHBP1 autoantibody syndrome during interferon β1a treatment.
Eguchi J; Miyashita K; Fukamachi I; Nakajima K; Murakami M; Kawahara Y; Yamashita T; Ohta Y; Abe K; Nakatsuka A; Mino M; Takase S; Okazaki H; Hegele RA; Ploug M; Hu X; Wada J; Young SG; Beigneux AP
J Clin Lipidol; 2019; 13(1):62-69. PubMed ID: 30514621
[TBL] [Abstract][Full Text] [Related]
5. GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.
Hu X; Dallinga-Thie GM; Hovingh GK; Chang SY; Sandoval NP; Dang TLP; Fukamachi I; Miyashita K; Nakajima K; Murakami M; Fong LG; Ploug M; Young SG; Beigneux AP
J Clin Lipidol; 2017; 11(4):964-971. PubMed ID: 28666713
[TBL] [Abstract][Full Text] [Related]
6. Chylomicronemia from GPIHBP1 autoantibodies.
Miyashita K; Lutz J; Hudgins LC; Toib D; Ashraf AP; Song W; Murakami M; Nakajima K; Ploug M; Fong LG; Young SG; Beigneux AP
J Lipid Res; 2020 Nov; 61(11):1365-1376. PubMed ID: 32948662
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome.
Paquette M; Hegele RA; Paré G; Baass A
J Clin Lipidol; 2018; 12(2):506-510. PubMed ID: 29452893
[TBL] [Abstract][Full Text] [Related]
8. Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.
Lin MH; Tian XH; Hao XL; Fei H; Yin JL; Yan DD; Li T
BMC Pregnancy Childbirth; 2020 May; 20(1):272. PubMed ID: 32375710
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene.
Rabacchi C; D'Addato S; Palmisano S; Lucchi T; Bertolini S; Calandra S; Tarugi P
J Clin Lipidol; 2016; 10(4):915-921.e4. PubMed ID: 27578123
[TBL] [Abstract][Full Text] [Related]
10. A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome.
Nimonkar AV; Weldon S; Godbout K; Panza D; Hanrahan S; Cubbon R; Xu F; Trauger JW; Gao J; Voznesensky A
J Biol Chem; 2020 Mar; 295(10):2900-2912. PubMed ID: 31645434
[TBL] [Abstract][Full Text] [Related]
11. Primary IgA-mediated Autoimmune Hemolytic Anemia in an Infant Successfully Treated With Rituximab.
van den Akker M; Smolders D; Mahieu S; Bonouvrie K; van der Werf Ten Bosch J
J Pediatr Hematol Oncol; 2020 Oct; 42(7):e615-e619. PubMed ID: 32118812
[TBL] [Abstract][Full Text] [Related]
12. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
13. Rituximab improved systemic lupus erythematosus-associated pulmonary alveolar proteinosis without decreasing anti-GM-CSF antibody levels.
Nagasawa J; Kurasawa K; Hanaoka R
Lupus; 2016 Jun; 25(7):783-4. PubMed ID: 26843507
[No Abstract] [Full Text] [Related]
14. GPIHBP1 missense mutations often cause multimerization of GPIHBP1 and thereby prevent lipoprotein lipase binding.
Beigneux AP; Fong LG; Bensadoun A; Davies BS; Oberer M; Gårdsvoll H; Ploug M; Young SG
Circ Res; 2015 Feb; 116(4):624-32. PubMed ID: 25387803
[TBL] [Abstract][Full Text] [Related]
15. Marked and sustained improvement on nerve conduction study of anti-myelin-associated glycoprotein neuropathy following rituximab therapy.
Al-Bustani N; Weiss MD
Muscle Nerve; 2016 Mar; 53(3):489-90. PubMed ID: 26501896
[No Abstract] [Full Text] [Related]
16. Microangiopathic antiphospholipid antibody syndrome due to anti-phosphatidylserine/prothrombin complex IgM antibody.
Senda Y; Ohta K; Yokoyama T; Shimizu M; Furuichi K; Wada T; Yachie A
Pediatr Int; 2017 Mar; 59(3):378-380. PubMed ID: 28317300
[TBL] [Abstract][Full Text] [Related]
17. Anti-desmoglein antibody-negative paraneoplastic pemphigus successfully treated with rituximab.
Kanwar AJ; Vinay K; Varma S; Koga H; Ishii N; Hashimoto T
Int J Dermatol; 2015; 54(5):576-9. PubMed ID: 24738571
[No Abstract] [Full Text] [Related]
18. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
[No Abstract] [Full Text] [Related]
19. [Progressive encephalitis due to anti-DPPX antibodies: a case with good response to treatment with rituximab].
Valero-Lopez G; Martin-Fernandez JJ; Hernandez-Clares R; Baidez-Guerrero AE; Martinez-Hernandez E
Rev Neurol; 2017 Dec; 65(11):525-526. PubMed ID: 29178111
[TBL] [Abstract][Full Text] [Related]
20. Evolution from one autoimmune disorder to another. Epitope spreading?
Karagianni P; Zampeli E; Moutsopoulos HM
Scand J Immunol; 2018 May; 87(5):e12657. PubMed ID: 29486064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
